CAS 71827-03-7
:Ivermectine B1a
- (2aE,4E,5'S,6S,6'R,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl (4xi)-2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-threo-hexopyranoside
- 22,23-Dihydro-5-O-demethylavermectin A1a
- 22,23-Dihydroavermectin B(1)a
- 22,23-Dihydroavermectin B1a
- 22,23-Dihydroavermectin B<sub>1a</sub>
- 5-O-Demethyl-22,23-dihydroavermectin A<sub>1a</sub>
- Avermectin A1a, 22,23-dihydro-5-O-demethyl-
- Avermectin A<sub>1a</sub>, 5-O-demethyl-22,23-dihydro-
- Brn 4643153
- Dihydroavermectin B1a
- Dihydroavermectin B<sub>1a</sub>
- Ivermectin B1a
- Ivermectin B<sub>1a</sub>
- Spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2′-[2H]pyran], avermectin A<sub>1a</sub> deriv.
- Unii-91Y2202Ouw
- Avermectin A1a, 5-O-demethyl-22,23-dihydro-
- 5-O-Demethyl-22,23-dihydroavermectin A1a
- Voir plus de synonymes
Ivermectin B1a-d2
CAS :Formule :C48H72D2O14Couleur et forme :White To Off-White SolidMasse moléculaire :877.12Ivermectin B1a
CAS :Formule :C48H74O14Couleur et forme :White To Off-White SolidMasse moléculaire :875.11Ivermectin B1a
CAS :Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.Formule :C48H74O14Degré de pureté :≥98%Couleur et forme :SolidMasse moléculaire :875.09Ivermectin B1a-D2
CAS :Produit contrôléApplications Ivermectin B1a-D2 is a deuterium labelled analogue of Ivermectin B1a (I940815), which is a major component of Ivermectin (I940800), a semi-synthetic derivative of Abamectin; consists of a mixture of not less than 80% component B1a and not more than 20% component B1b. Antihelmintic (Onchocerca). An invitro inhibitor of SARS-CoV-2/ Covid-19.
References Chabala, J.C., et al.: J. Med. Chem., 23, 1134 (1980); Campbell, W.C., et al.: Science, 221, 823 (1983); Bennett, J.L., et al.: Parasitol. Today, 4, 226 (1988); Plaisier, A.P., et al.: J. Infect. Dis., 172, 204 (1995);; Caly, L., et al.: Antivir. Res., 178Formule :C48H72D2O14Couleur et forme :NeatMasse moléculaire :877.11Ivermectin B1a (>85%)
CAS :Produit contrôléApplications Ivermectin B1a is a major component of Ivermectin (I940800), a semi-synthetic derivative of Abamectin; consists of a mixture of not less than 80% component B1a and not more than 20% component B1b. Antihelmintic (Onchocerca). An invitro inhibitor of SARS-CoV-2/ Covid-19.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Chabala, J.C., et al.: J. Med. Chem., 23, 1134 (1980); Campbell, W.C., et al.: Science, 221, 823 (1983); Bennett, J.L., et al.: Parasitol. Today, 4, 226 (1988); Plaisier, A.P., et al.: J. Infect. Dis., 172, 204 (1995);; Caly, L., et al.: Antivir. Res., 178Formule :C48H74O14Degré de pureté :>85%Couleur et forme :NeatMasse moléculaire :875.09Ivermectin B1a-D2
CAS :Ivermectin is a broad-spectrum antiparasitic agent that is used to treat onchocerciasis and other infectious diseases. It binds selectively to gamma-aminobutyric acid (GABA) receptors in the central nervous system and inhibits the release of neurotransmitters, thereby inhibiting the inflammatory response. Ivermectin has been shown to be safe for use in humans and has a long half-life that allows for once-weekly administration. This drug also has pharmacokinetic properties that are similar among different species and clinical studies have shown no significant differences between human and animal models. Ivermectin is applied topically as an ointment or cream or orally as tablets or capsules, depending on the condition being treated.Formule :C48H72D2O14Degré de pureté :Min. 95%Masse moléculaire :877.11 g/mol






